<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000433</url>
  </required_header>
  <id_info>
    <org_study_id>N01 AR92244</org_study_id>
    <secondary_id>NIAMS-043</secondary_id>
    <nct_id>NCT00000433</nct_id>
  </id_info>
  <brief_title>Blocking Tumor Necrosis Factor in Ankylosing Spondylitis</brief_title>
  <official_title>Anti-Tumor Necrosis Factor (TNFR:Fc) in Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</source>
  <brief_summary>
    <textblock>
      The Division of Rheumatology at University of California San Francisco is conducting a&#xD;
      research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently&#xD;
      used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a&#xD;
      protein that is given twice weekly by injection underneath the skin. It blocks the action of&#xD;
      tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid&#xD;
      arthritis, and other inflammatory conditions. We will randomly assign patients to receive&#xD;
      either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor&#xD;
      include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase II clinical trial we will use tumor necrosis factor receptor p75 fusion protein&#xD;
      (TNFR:Fc, or etanercept) to treat patients with ankylosing spondylitis (AS). TNFR:Fc is an&#xD;
      antagonist of tumor necrosis factor (TNF), a cytokine that researchers have shown to play a&#xD;
      possible role in disease pathogenesis of ankylosing spondylitis, rheumatoid arthritis, and&#xD;
      vasculitis, as well as other inflammatory conditions.&#xD;
&#xD;
      TNFR:Fc consists of two molecules of the extracellular portion of the p75 receptor, each&#xD;
      consisting of 235 amino acids. The two receptors are fused to the Fc portion of human IgG1,&#xD;
      which consists of 232 amino acids. The gene fragments encoding the truncated TNFR and the Fc&#xD;
      portion of human IgG1 are expressed in a Chinese hamster ovary cell line.&#xD;
&#xD;
      Recent observations from animal and human studies suggest that tumor necrosis factor-alpha&#xD;
      (TNF-alpha) may play a role in disease activity in AS and other seronegative&#xD;
      spondyloarthropathies. This study aims to test the efficacy of TNFR:Fc used in conjunction&#xD;
      with standard medications in the treatment of AS. We will give patients either 25mg of&#xD;
      TNFR:Fc or placebo subcutaneously twice a week for 4 months. Outcome measures will include&#xD;
      measures of function, pain, morning stiffness, patient global assessment, and swollen joint&#xD;
      count, as well as safety measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date>March 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>42</enrollment>
  <condition>Spondylitis, Ankylosing</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Tumor Necrosis Factor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Ankylosing spondylitis&#xD;
&#xD;
          -  Acceptable stable treatments during study: oral glucocorticoids (less than or equal to&#xD;
             10 mg/d) and/or NSAIDs at recommended doses and/or one of the following options:&#xD;
             methotrexate (less than or equal to 20.0 mg/week); sulfasalazine (less than or equal&#xD;
             to 3 grams/d); azathioprine (less than or equal to 2 mg/kg/d); methotrexate and&#xD;
             sulfasalazine combination at doses listed above; 6-mercaptopurine (less than or equal&#xD;
             to 1.5 mg/kg/d)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of psoriatic arthritis, inflammatory bowel disease, reactive arthritis, or&#xD;
             Beh√Ωet disease&#xD;
&#xD;
          -  Significant medical problems, such as diabetes mellitus&#xD;
&#xD;
          -  History of active or recurrent infections&#xD;
&#xD;
          -  Complete ankylosis of the entire spine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C. Davis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Rheumatology, University of California - San Francisco Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF-Clinical Trials Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349-56. doi: 10.1056/NEJMoa012664.</citation>
    <PMID>11986408</PMID>
  </reference>
  <reference>
    <citation>Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov;48(11):3230-6. doi: 10.1002/art.11325.</citation>
    <PMID>14613288</PMID>
  </reference>
  <reference>
    <citation>Davis JC Jr, Huang F, Maksymowych W. New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Rheum Dis Clin North Am. 2003 Aug;29(3):481-94, viii. doi: 10.1016/s0889-857x(03)00028-0.</citation>
    <PMID>12951863</PMID>
  </reference>
  <verification_date>February 2003</verification_date>
  <study_first_submitted>January 18, 2000</study_first_submitted>
  <study_first_submitted_qc>January 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2000</study_first_posted>
  <last_update_submitted>January 2, 2007</last_update_submitted>
  <last_update_submitted_qc>January 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2007</last_update_posted>
  <keyword>Spondylitis</keyword>
  <keyword>Etanercept</keyword>
  <keyword>ENBREL</keyword>
  <keyword>Tumor necrosis factor-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

